Evaluating anti-idiotypic antibodies as novel vaccine candidates against HIV-1

评估抗独特型抗体作为针对 HIV-1 的新型候选疫苗

基本信息

  • 批准号:
    10540731
  • 负责人:
  • 金额:
    $ 36.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-12-06 至 2024-11-30
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract Broadly neutralizing antibodies (bNAbs) that bind to the HIV-1 Envelope glycoprotein (Env) are expected to be an important component of the immune response elicited by an effective HIV-1 vaccine. However, efforts to elicit bNAbs through vaccination with recombinant Env have not yet been successful. VRC01-class antibodies are among the broadest and most potent bNAbs that have been isolated from infected individuals, and their elicitation would be an ideal goal of a vaccine. VRC01-class antibodies have been isolated from multiple donors, and they all interact with Env in a nearly identical manner; are derived from the same antibody heavy chain gene, VH1-2*02; and have an unusually short third complimentary determining region (CDRL3) on the light chain. During the course of infection, VRC01-class antibodies acquired a number of mutations in their antibody genes that allow them recognize and neutralize diverse HIV-1 viral isolates. Using sequence homology, one can predict the sequence of the B-cell receptor (BCR) on the naive B cell that gave rise to each VRC01-class antibody. Previous work from our group and others has demonstrated that these inferred-germline versions of VRC01-class antibodies fail to recognize diverse recombinant Envs. Thus, conventional Env immunogens are likely ineffective at binding to and activating naive B cells that can give rise to VRC01-class antibodies. The structural similarity and shared genetics of VRC01-class antibodies have led to the proposal that immunogens designed to specifically to engage VRC01-class precursor B cells could, at the very least, start the process of VRC01-class antibody production. Indeed we, and others, have designed Env-based immunogens that can activate B cells expressing VRC01-class precursor BCRs in vitro and in vivo. However, these immunogens also present off-target, potentially immunodominant epitopes that could ultimately frustrate the development of VRC01-class antibodies in competitive germinal center reactions. As an alternative to Env-derived immunogens, we have produced and isolated anti-idiotypic antibodies that are highly specific for the antigen binding site of VRC01-class precursor BCRs. Importantly, because they are non-Env derived, they lack the off-target epitopes present on other germline-targeting immunogens. Our overarching hypothesis is that if used as a vaccine prime, anti-idiotypic antibodies can selectively seek out and expand rare VRC01-class B cells, such that the expanded pool will have a selective advantage over other B cells that respond to off-target epitopes following a boost with germline-targeting Env. This hypothesis will be tested in transgenic mouse models as part of this HIVRAD application, in collaboration with Drs. Stamatatos and Nussenzweig. The focus of this project is to evaluate the ability of these novel immunogens to seek out rare VRC01-class precursor B cells from human PBMC samples and from mice expressing a diverse human-derived BCR repertoire, and to engineer multivalent aiMAb derivatives to improve immunogenicity.
项目总结/文摘

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Andrew McGuire其他文献

Andrew McGuire的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Andrew McGuire', 18)}}的其他基金

Development of an anti-idiotype based vaccine for respiratory syncytial virus
呼吸道合胞病毒抗独特型疫苗的研制
  • 批准号:
    10593361
  • 财政年份:
    2021
  • 资助金额:
    $ 36.91万
  • 项目类别:
Development of an anti-idiotype based vaccine for respiratory syncytial virus
呼吸道合胞病毒抗独特型疫苗的研制
  • 批准号:
    10414112
  • 财政年份:
    2021
  • 资助金额:
    $ 36.91万
  • 项目类别:
Development of an anti-idiotype based vaccine for respiratory syncytial virus
呼吸道合胞病毒抗独特型疫苗的研制
  • 批准号:
    10302873
  • 财政年份:
    2021
  • 资助金额:
    $ 36.91万
  • 项目类别:
Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex
定义针对 EBV gH/gL 糖蛋白复合物的抗体的保护功效
  • 批准号:
    10593368
  • 财政年份:
    2019
  • 资助金额:
    $ 36.91万
  • 项目类别:
Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex
定义针对 EBV gH/gL 糖蛋白复合物的抗体的保护功效
  • 批准号:
    10199986
  • 财政年份:
    2019
  • 资助金额:
    $ 36.91万
  • 项目类别:
Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex
定义针对 EBV gH/gL 糖蛋白复合物的抗体的保护功效
  • 批准号:
    10455109
  • 财政年份:
    2019
  • 资助金额:
    $ 36.91万
  • 项目类别:
Defining the protective efficacy of antibodies against the EBV gH/gL glycoprotein complex
定义针对 EBV gH/gL 糖蛋白复合物的抗体的保护功效
  • 批准号:
    10669738
  • 财政年份:
    2019
  • 资助金额:
    $ 36.91万
  • 项目类别:
Evaluating anti-idiotypic antibodies as novel vaccine candidates against HIV-1
评估抗独特型抗体作为针对 HIV-1 的新型候选疫苗
  • 批准号:
    10062817
  • 财政年份:
    2018
  • 资助金额:
    $ 36.91万
  • 项目类别:
Evaluating anti-idiotypic antibodies as novel vaccine candidates against HIV-1
评估抗独特型抗体作为针对 HIV-1 的新型候选疫苗
  • 批准号:
    10300442
  • 财政年份:
    2018
  • 资助金额:
    $ 36.91万
  • 项目类别:
Evaluating anti-idiotypic antibodies as novel vaccine candidates against HIV-1
评估抗独特型抗体作为针对 HIV-1 的新型候选疫苗
  • 批准号:
    10593447
  • 财政年份:
    2018
  • 资助金额:
    $ 36.91万
  • 项目类别:

相似海外基金

Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
  • 批准号:
    23H01982
  • 财政年份:
    2023
  • 资助金额:
    $ 36.91万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
  • 批准号:
    23KJ0116
  • 财政年份:
    2023
  • 资助金额:
    $ 36.91万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
  • 批准号:
    10598276
  • 财政年份:
    2023
  • 资助金额:
    $ 36.91万
  • 项目类别:
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
  • 批准号:
    10682794
  • 财政年份:
    2023
  • 资助金额:
    $ 36.91万
  • 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233343
  • 财政年份:
    2023
  • 资助金额:
    $ 36.91万
  • 项目类别:
    Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
  • 批准号:
    2233342
  • 财政年份:
    2023
  • 资助金额:
    $ 36.91万
  • 项目类别:
    Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
  • 批准号:
    479363
  • 财政年份:
    2023
  • 资助金额:
    $ 36.91万
  • 项目类别:
    Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
  • 批准号:
    10681989
  • 财政年份:
    2023
  • 资助金额:
    $ 36.91万
  • 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
  • 批准号:
    2237240
  • 财政年份:
    2023
  • 资助金额:
    $ 36.91万
  • 项目类别:
    Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
  • 批准号:
    2305592
  • 财政年份:
    2023
  • 资助金额:
    $ 36.91万
  • 项目类别:
    Continuing Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了